Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Trial Title: Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

NCT ID: NCT05851365

Condition: Prostate Cancer
Localized Prostate Carcinoma

Conditions: Official terms:
Prostatic Neoplasms

Conditions: Keywords:
Tissue pH
Magnetic Resonance (MR) Imaging

Study type: Interventional

Study phase: Early Phase 1

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Hyperpolarized Bicarbonate (13C)
Description: Given IV
Arm group label: Pre-surgical participants with prostate cancer

Other name: Hyperpolarized (HP) bicarbonate 13 (13C)

Other name: HP C13

Intervention type: Procedure
Intervention name: Magnetic Resonance imaging
Description: Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
Arm group label: Pre-surgical participants with prostate cancer

Other name: Magnetic Resonance scan

Other name: MR scan

Summary: This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen (pH) values in surrounding tissue. The proposed study will evaluate pre-surgical participants with histologically confirmed localized prostate cancer who receive infusion of hyperpolarized 13C injection prior to MR imaging with endorectal coil.

Detailed description: PRIMARY OBJECTIVE: I. To determine the feasibility of tumor pH measurement in men with prostate cancer using hyperpolarized 13C bicarbonate imaging. SECONDARY OBJECTIVE: I. To determine the safety of administration of hyperpolarized 13C-bicarbonate. EXPLORATORY OBJECTIVES: I. To correlate the measurement of tissue pH with pathologic grade. II. To correlate tissue pH maps with immunohistochemistry staining (IHC), gene expression (RNA-Seq), and spatial transcriptomics. *Bristol Myers Squibb (BMS) collaboration OUTLINE: Men with biopsy-proven adenocarcinoma of the prostate scheduled to undergo radical prostatectomy at University of California, San Francisco (UCSF) within 12 weeks of enrollment will receive infusion with hyperpolarized 13C bicarbonate and undergo metabolic MR imaging with endorectal coil. Participants will be followed for 5-9 days after the hyperpolarized 13C-bicarbonate injection, or removal from study, or until death, whichever occurs first. Participants removed from study for unacceptable study related adverse event(s) will be followed until resolution or stabilization (as determined by the investigator) or until initiation of new anti-cancer therapy, whichever occurs first.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Patients age >=18 years. 2. Patients must have biopsy-proven adenocarcinoma of the prostate; biopsy may be performed outside of University of California, San Francisco (UCSF) if detailed results of sextant biopsy are available. 3. Tumor size of at least 1.0 cm in long axis on Magnetic resonance imaging (MRI) or ultrasound; if no prior imaging is available, at least 3 cores positive on biopsy. 4. Patients must have planned radical prostatectomy at UCSF within 12 weeks following protocol MRI/ magnetic resonance spectroscopy imaging) (MRSI). 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 6. Demonstrates adequate organ function as defined below: 1. Adequate bone marrow function: - Absolute neutrophil count >=1,500 cells/µL. - Platelets >=75,000 cells/µL. - Hemoglobin >=9.0 gm/dL. 2. Adequate hepatic function: - Total bilirubin <1.5x upper limits of normal (ULN) (within normal institutional limits, unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits). - Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) <=1.5 X institutional upper limit of normal. - Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <=1.5 X institutional upper limit of normal. 3. Adequate renal function: - Creatinine clearance >= 50 calculated using the Cockcroft-Gault equation, unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2. 7. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Patients who because of general medical or psychiatric condition, or physiologic status, cannot give valid informed consent. 2. Patients unwilling or unable to undergo MR imaging, including patients with contraindications to Magnetic resonance imaging (MRI) as per UCSF radiology departmental guidelines. 3. Patients who cannot tolerate or have contra-indications to endorectal coil insertion, for example, patients with a prior abdominoperineal resection of the rectum or latex allergy. 4. Patients with contra-indications to injection of gadolinium contrast as per UCSF radiology departmental guidelines. 5. Patients who take carbonic anhydrase inhibitors (e.g. acetazolamide, dichlorphenamide, methazolamide). 6. Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging. 7. Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment. No limit on number of prior prostate biopsies. Prior Transurethral Resection of the Prostate (TURP) is not allowed. 8. Poorly controlled hypertension, with blood pressure at study entry >160/100. The addition of anti-hypertensives to control blood pressure is allowed for eligibility determination. 9. Congestive heart failure or New York Heart Association (NYHA) status >= 2. A history of clinically significant electrocardiogram (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: University of California, San Francisco

Address:
City: San Francisco
Zip: 94143
Country: United States

Status: Recruiting

Contact:
Last name: Maya Aslam

Phone: 415-514-8987
Email: Maya.Aslam@ucsf.edu

Contact backup:

Phone: 877-827-3222
Email: cancertrials@ucsf.edu

Investigator:
Last name: Robert Flavell, MD, PhD
Email: Principal Investigator

Start date: July 6, 2023

Completion date: December 31, 2025

Lead sponsor:
Agency: Robert Flavell, MD, PhD
Agency class: Other

Collaborator:
Agency: U.S. Army Medical Research Acquisition Activity
Agency class: U.S. Fed

Collaborator:
Agency: Bristol-Myers Squibb
Agency class: Industry

Source: University of California, San Francisco

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05851365